Evotec
Evotec SE, a leading global biotechnology company headquartered in Germany, is renowned for its innovative drug discovery and development solutions. Founded in 1993, Evotec has established a strong presence in Europe, North America, and Asia, focusing on areas such as central nervous system disorders, metabolic diseases, and oncology. The company offers a unique platform that integrates cutting-edge technologies and extensive expertise, enabling efficient and effective drug development processes. Notable achievements include strategic partnerships with major pharmaceutical firms, positioning Evotec as a key player in the biopharmaceutical industry. With a commitment to advancing healthcare, Evotec continues to drive progress in the development of novel therapeutics, making significant contributions to the global fight against disease.
DitchCarbon Score
How does Evotec's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Evotec's score of 62 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Evotec's reported carbon emissions
In 2023, Evotec SE reported total greenhouse gas emissions of approximately 299,948,000 kg CO2e. This includes 15,720,000 kg CO2e from Scope 1 emissions and 11,554,000 kg CO2e from Scope 2 emissions, with a significant contribution of 272,674,000 kg CO2e from Scope 3 emissions. Evotec has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its value chain by 2045. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 50.4% by 2032, using 2021 as the baseline year. Additionally, Evotec plans to increase its sourcing of renewable electricity from 25% in 2021 to 100% by 2026 and maintain this level through 2030. For Scope 3 emissions, Evotec aims to achieve a 72% reduction per million EUR value added by 2032. Furthermore, the company is committed to ensuring that 80% of its suppliers, based on emissions from purchased goods and services and capital goods, will have science-based targets by 2027. Long-term, Evotec targets a 95% reduction in Scope 1 and 2 emissions and a 97% reduction in Scope 3 emissions by 2045. These initiatives reflect Evotec's commitment to sustainability and its proactive approach to addressing climate change within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 28,000 | 00,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Evotec is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
